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Abstract Myasthenia gravis (MG) and its animal model, ex-
perimental autoimmune MG (EAMG), are mainly caused by
autoantibodies directed against acetylcholine receptors (AChR)
located in the postsynaptic muscle membrane. Previously, we
isolated an RNA aptamer with 2P-£uoropyrimidines using in
vitro selection techniques that acted as an e¡ective decoy
against both a rat monoclonal antibody called mAb198, which
recognizes the main immunogenic region on the AChR, and a
signi¢cant fraction of patient autoantibodies with MG. To in-
vestigate the therapeutic potential of the RNA, we tested the
ability of the RNA aptamer to protect the receptors in vivo from
mAb198. Clinical symptoms of EAMG in rats engendered by
passive transfer of mAb198 were e⁄ciently inhibited by a trun-
cated RNA aptamer that was modi¢ed with polyethylene glycol,
but not by control scrambled RNA. Moreover, the loss of AChR
in the animals induced by the antibody was also signi¢cantly
blocked with the modi¢ed RNA aptamer. These results sug-
gested that RNA aptamers could be applied for antigen-speci¢c
treatment for autoimmune diseases including MG.
0 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Myasthenia gravis (MG) is a neuromuscular disorder asso-
ciated with muscular weakness and fatigability. The patho-
genesis of MG mainly results from antibody-mediated auto-
immune response to nicotinic acetylcholine receptors (AChR)
located in the postsynaptic muscle cell membrane [1]. Exper-
imental autoimmune myasthenia gravis (EAMG) can be gen-
erated in animals by active immunization with puri¢ed AChR
or passive transfer of anti-AChR antibodies [2]. The majority
of anti-AChR antibodies found in both human patients with
MG and rats with EAMG bind to the main immunogenic
region (MIR) on the extracellular domain of the AChR
K-subunit [3,4]. Such autoantibodies cause internalization
and degradation of the AChR available on the skeletal muscle
at neuromuscular junctions, resulting in the failure of neuro-
transmission and paralysis [1,2]. Because the current MG
therapies including general immunosuppression often cause
toxic side e¡ects [1], development of agents that can more
speci¢cally inhibit MG is warranted.
Since the pathogenesis of MG is mainly due to autoanti-
bodies to AChR, much e¡ort has been directed toward the
development of small molecules that block interaction of the
antibodies with the receptors [5^7]. Short RNA aptamers that
have been isolated to a wide range of proteins with iterative in
vitro selection techniques from a combinatorial RNA library
[8,9] have been reported to act as speci¢c decoys and inhibit
the physiological functions known to be associated with the
target proteins in cells and in animal models [10]. The ration-
ale of these experiments is that a short RNA molecule with
certain sequence can form a fairly stable and unique tertiary
structure via intramolecular base-pairing [11]. Noticeably, at-
tachment of a polyethylene glycol (PEG) to the 5P end of an
aptamer has been shown to enhance in vivo bioavailability of
the aptamer [12,13]. Thus, RNA molecules could be alterna-
tive candidates for speci¢c and e¡ective inhibitors of MG
autoantibodies.
Previously, we employed in vitro selection methods and
successfully isolated a short and nuclease-resistant RNA ap-
tamer with 2P-amino- [14] or 2P-£uoro-modi¢ed pyrimidines
[15] that can bind both a rat monoclonal antibody, called
mAb198, that is speci¢c to the MIR on human AChR, and
patient autoantibodies with MG with high speci¢city and high
a⁄nity. Surprisingly, the sequence of the RNA aptamer
with 2P-£uoropyrimidines was the same as that of RNA
with 2P-aminopyrimidines [15]. These RNA aptamers have
been shown to act as decoys to protect AChR from the e¡ects
of the antibodies in human cells. Moreover, we could improve
binding activity and bioactivity of the RNA aptamer with
2P-amino by extended sequence selection [16]. In this study,
we present the ability of the RNA aptamer to inhibit EAMG
in animal models. We demonstrated that the selected RNA
aptamer with 2P-£uoropyrimidines that was truncated and
modi¢ed by attachment of PEG at its 5P end showed no sig-
ni¢cant di¡erences in binding a⁄nity to mAb198 and bioac-
tivities protecting AChR on human cells from both mAb198
and patient autoantibodies, compared to the unmodi¢ed
2P-£uoro RNA aptamer. Moreover, the modi¢ed aptamer
protected clinical symptoms of EAMG in animals passively
transferred by mAb198 and blocked the antibody-mediated
loss of muscle AChR in the animals.
2. Materials and methods
2.1. Antibodies, AChR, and cells
Rat anti-MIR mAb198 and rat hybridoma cell lines producing
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mAb198, kindly provided by Jon Lindstrom (University of Pennsyl-
vania, Philadelphia, PA, USA), were prepared, and characterized as
described [6]. Serum samples from a patient with MG (batch #2051)
were purchased from The Binding Site (San Diego, CA, USA). Ac-
cording to the manufacturer, the radioimmunoassay titer of anti-hu-
man AChR in the patient’s serum was very high. The major extracel-
lular domain of the human AChR K-subunit (amino acids 1^210) was
a gift from Sohel Talib (Gencell, Santa Clara, CA, USA). The TE671
human medulloblastoma cell line (ATCC 8805-CRL) of rhabdomyo-
sarcoma origin [17] expresses receptors for acetylcholine apparently
identical to human AChR [18] and was used in AChR down-modu-
lation experiments.
2.2. Preparation and analysis of selected RNA aptamer
Full-length RNA aptamer with 2P-deoxy-2P-£uoropyrimidines (Am-
bion) previously selected against mAb198 or its truncated form (fMG
RNA or tMG RNA, respectively) was synthesized by in vitro tran-
scription of synthetic DNA templates, radiolabeled, and isolated as
described [15,19]. The sequence of fMG RNA was 5P-GGGAGAG-
CGGAAGCGUGCUGGGCCGGAGGUUAGCUUGCCCAUGGCA-
AGCAGGGCGCCACGGACCCAUAACCCAGAGGUCGAUGGA-
CAUAACCCAGAGGUCGAUGGAUCCC-3P, where the under-
lined sequence represents selected nucleotides (nt) and the 46-nt-long
truncated sequence in italics is a minimal binding domain. Truncated
RNA aptamer was coupled to 40-kDa PEG to its 5P end (Peg-tMG
RNA) to increase its residence time in animal plasma as described
[20]. For binding a⁄nity assays, competition binding was performed
by incubating 100 pM of 32P-labeled fSE RNA, 50 nM mAb198, and
excess amount of unlabeled competitor RNA in 100 Wl binding bu¡er
(30 mM Tris^HCl, pH 7.5, 150 mM NaCl, 10 mM MgCl2, 2 mM
dithiothreitol, and 1% bovine serum albumin) for 30 min at room
temperature with shaking. Antibody^RNA complexes were immuno-
precipitated with 20 Wl of protein G-Sepharose beads (Pharmacia
Biotech), and bound RNAs eluted from the pellets and analyzed on
a 6% polyacrylamide gel with urea. The percentage of RNA bound to
mAb198 was calculated as the fraction of radioactivity present in the
antibody^RNA complexes in the absence of any competitors. The Kd
of the competitor RNA was estimated to be equivalent to its 50%
inhibitory concentration as described [21].
2.3. Assay of AChR down-modulation
AChR down-modulation was monitored as described [14^16].
MAb198 (5 nM) or autoantibodies from a patient with MG were
preincubated in 90 Wl of Dulbecco’s modi¢ed Eagle’s medium con-
taining 10 mM MgCl2, 1% bovine serum albumin, and 10% fetal
bovine serum with tested RNA for 30 min at room temperature.
These mixtures were then added to TE671 cells in the presence of
40 Wg/ml of cycloheximide and incubated at 37‡C for 4 h. Next,
10 Wl of medium with 50 nM of 125I-radiolabeled K-bungarotoxin
(K-Bgt) was added and incubated for 3 h more. The cells were then
washed, and the bound K-Bgt was quantitated using a Q 5000 counter
(Packard Instruments). Incubation of TE671 cells with 5 nM of
mAb198 by itself reproducibly reduced AChR expression of the cell
surface by approximately 50%. This level of antigenic down-modula-
tion was considered 100%, and other values were normalized to this
amount. For antigenic down-modulation experiments with patient
autoantibodies, patient sera were added to TE671 cells at concentra-
tions determined to engender similar levels of antigenic down-modu-
lation as 5 nM of mAb198: 1 Wl of 1:2 dilution of patient sera (data
not shown).
2.4. Prevention of EAMG in rats
Six-week-old female Lewis rats weighing 100^150 g were used for
i.p. passive transfer of 100 Wg of mAb198 in phosphate-bu¡ered saline
(PBS). The e¡ect of RNA aptamer was analyzed by injecting a mix-
ture of mAb198 and RNA aptamer after preincubation for 1 h at
room temperature. To ensure that intact RNA aptamer was continu-
ously present in the circulation, the aptamer was injected two more
times. There was no signi¢cant inhibition of EAMG with only initial
single input of the RNA. Twenty-four hours after mAb198 injection
the rats were assessed for EAMG symptoms and scored according to
the following grade: 0, normal; 1, weak grasp after a few trials; 2,
incomplete paralysis of hind limbs; 3, severe paralysis and moribund;
and 4, death. Rats with intermediate symptoms were scored with
intermediate scales. At the end of the experiment, the rats were killed
and the AChR content in the extract of hind limb muscles of each rat
was monitored by radioimmunoassay as described [22]. The values
were expressed as a percentage of the AChR amount in rats injected
only with PBS.
3. Results and discussion
3.1. Binding a⁄nity of RNA aptamer to mAb198
Previously, we isolated an 89-nt-long nuclease-resistant
RNA aptamer, termed fMG RNA, which bound to
mAb198 very avidly (KdW25 nM) and speci¢cally, from a
large (V1014 molecules) combinatorial RNA library with
every pyrimidine modi¢ed at its 2P position by a £uoro group
[15]. For the scale of e⁄cient synthesis necessary for in vivo
applications, however, fMG RNA must be shortened to at
most 50 nt. A 46-nt-long truncated version of fMG RNA,
termed tMG RNA, was observed to contain the most critical
sequences for mAb198 binding from deletion mapping analy-
sis (Fig. 1A, data not shown). Scrambling the ¢ve nucleotides
that form the internal loop of tMG RNA disrupted the ap-
tamer binding to mAb198 (Fig. 1B), hence this RNA (Scram-
ble RNA) was used as a negative control for tMG RNA. For
the assessment of in vivo activity of the aptamer, Peg-tMG
RNA was generated because its conjugation to an RNA ap-
Fig. 1. Sequence, structure, and binding a⁄nity of RNA aptamer
isolated against mAb198. A: Predicted secondary structure of tMG
RNA, a 46-nt truncate of a full-length RNA aptamer (fMG RNA)
to mAb198, was determined using the MULFOLD program [27].
Mutation of ¢ve nucleotides in tMG RNA yields an inactive ap-
tamer, Scramble RNA. B: The percentage of fMG RNA bound to
mAb198, normalized to binding in the absence of any competitor
RNA, was plotted as a function of each competitor RNA (tMG
RNA, Peg-tMG RNA, or Scramble RNA). Values shown are aver-
ages of measurements performed in triplicate, and bars indicate
standard errors.
FEBS 27472 15-7-03
B. Hwang et al./FEBS Letters 548 (2003) 85^8986
tamer with small size has been shown to reduce rapid tissue
di¡usion and renal clearance of the aptamer [12,13].
To determine the binding a⁄nity of the truncated aptamers,
a competition binding assay was carried out by incubation of
trace amounts of radiolabeled fMG RNA and increasing
amounts of unlabeled competitor RNA (Fig. 1B). An equilib-
rium dissociation constant (Kd) of 30 nM, an a⁄nity that was
very similar to that of fMG RNA (Kd of 25 nM), was detected
for tMG RNA. Moreover, the binding a⁄nity of Peg-tMG
RNA (Kd of 75 nM) to mAb198 was only about three-fold
less than that of fMG RNA. Thus, both a truncated version
of the selected RNA aptamer against mAb198 and its PEG-
conjugated form retain high a⁄nity of the aptamer to the
antibody. By contrast, Scramble RNA could hardly displace
the binding of fMG RNA to mAb198 even at the highest
concentration of RNA, indicating that mutation of the inter-
nal loop regions disrupts the aptamer’s binding activity to the
antibody.
3.2. Inhibition of autoantibody-mediated antigenic modulation
of AChR expression by RNA aptamer
Once it was ascertained that the truncated and modi¢ed
RNA aptamer with PEG bound to mAb198 with high a⁄nity,
we next determined if the RNA could protect AChR on hu-
man cells from the e¡ects of mAb198. Incubation of human
TE671 cells with mAb198 resulted in a dose- and time-depen-
dent degradation of AChR on the cell surface (data not
shown) [23], which is referred to as antigenic down-modula-
tion. To assess the modi¢ed aptamer’s ability to inhibit anti-
genic down-modulation induced by the antibody, TE671 cells
were incubated with mAb198 in the presence or absence of the
RNAs (Fig. 2A). AChR degradation was assessed by measur-
ing the amount of [125I]K-Bgt that could bind the AChRs
remaining on the cells after treatment with the antibody, as
previously described [14]. While a negative control RNA com-
petitor, such as Scramble RNA, showed little inhibition of the
mAb198-mediated AChR down-modulation, fMG RNA
showed e⁄cient protection of TE671 cells from the antibody
and inhibited AChR down-modulation by up to 65% as pre-
viously shown [15]. Moreover, both tMG RNA and Peg-tMG
RNA also e⁄ciently blocked TE671 cells from mAb198 and
inhibited antigenic down-modulation by up to 62% and 50%,
respectively. Furthermore, inhibition of AChR down-modula-
tion with the aptamers was dose-dependent (data not shown).
Thus, truncation and PEG conjugation of the RNA aptamer
selected against mAb198 showed no signi¢cant di¡erence in
the protection of cells from the antibody, compared with the
originally selected fMG RNA.
We have previously observed that fMG RNA could cross-
react with anti-AChR autoantibodies from MG patient sera.
This result was probably due to the fact that most patholog-
ically relevant autoantibodies from MG patients appear to
bind the AChR’s MIR that was recognized by mAb198
[2,24]. However, the RNA blocked a certain fraction of the
antibodies in the MG patient sera from binding to, and hence
the down-modulation of, AChR on TE671 cells with patient
variability [15]. This is probably due to di¡erent immune re-
sponses against AChR in the di¡erent individuals. Neverthe-
less, fMG RNA could inhibit the autoantibodies at least in
one patient in a dose-dependent manner almost as well as it
could protect cells from mAb198. Thus, we wanted to deter-
mine if the modi¢ed RNA aptamer could inhibit the down-
modulation of AChR expression mediated by autoantibodies
in the patient sera (Fig. 2B). Addition of fMG RNA, but not
control RNA such as Scramble RNA, protected a signi¢cant
fraction of AChR on TE671 cells from the patient’s autoanti-
bodies, and inhibited the AChR down-modulation by 47%.
Truncated tMG RNA and Peg-tMG RNA also e⁄ciently
protected a certain fraction of the cells from the autoantibod-
ies, and inhibited the antigenic down-modulation by 43% and
35%, respectively. Thus, truncation and PEG conjugation of
the RNA aptamer against mAb198 did not severely a¡ect the
aptamer’s ability to block AChR down-modulation mediated
by the most inhibited patient sera.
3.3. Inhibition of mAb198-mediated passive transfer of EAMG
in rats by RNA aptamer
Once the truncated and modi¢ed RNA aptamer with PEG
was shown to interact with mAb198 with high a⁄nity and
inhibited AChR degradation induced by autoantibodies in
cells, we examined whether the modi¢ed RNA aptamer could
block EAMG generated by mAb198 to evaluate the therapeu-
tic potential of the RNA aptamer (Fig. 3). Severe muscular
weakness was observed in 6-week-old rats within 24 h after a
Fig. 2. Inhibition of antigenic down-modulation mediated by either
mAb198 (A) or patient serum with MG (B) in cells with RNA ap-
tamers. A: TE671 cells were incubated with 5 nM of normal IgG,
5 nM of mAb198 alone, or mAb198 (5 nM) preincubated with 5 WM
of each RNA aptamer (fMG RNA, tMG RNA, Peg-tMG RNA, or
Scramble RNA). Down-modulation of AChR expression on the cell
surface was analyzed by [125I]K-Bgt binding. Values were expressed
as a percentage of AChR down-modulation engendered by mAb198
alone (5 nM). Values shown represent the meansRS.D. of three
separate determinations. B: TE671 cells were incubated with 1 Wl
normal human serum, or 1 Wl of 1:2 dilution of MG patient serum
either alone or after preincubation with 5 WM of each RNA ap-
tamer. AChR down-modulation was measured as described.
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single i.p. injection of 0.1 mg of mAb198 (Fig. 3A). However,
this progression of clinical symptoms induced by the antibody
was greatly reduced by repeated injection of Peg-tMG RNA.
By contrast, non-PEG-conjugated tMG RNA showed only
mild abolition of EAMG even with repeated treatment, indi-
cating that the increase in the circulation residence of the
RNA aptamer in animals by PEG conjugation was truly im-
portant for the improvement of in vivo bioavailability of the
aptamer. Noticeably, PEG-conjugated Scramble RNA (Peg-
Scr. RNA) hardly prevented EAMG signs induced by
mAb198. Thus, the protective e¡ect of Peg-tMG RNA against
EAMG in animals is not due to the non-speci¢c e¡ect that
PEG-conjugated RNA from itself might have, but due to the
speci¢c binding of the RNA aptamer with mAb198. Animals
injected only with the modi¢ed RNA aptamer showed no
signs of EAMG (data not shown). To con¢rm the inhibition
of EAMG by Peg-tMG RNA, we measured the muscle con-
centration of AChR in the hind limb by radioimmunoassay at
24 h following injection of mAb198 with or without RNA
aptamers (Fig. 3B). Control animals injected with mAb198
alone lost almost 51% of their muscular AChR content, as
reported, whereas animals treated with Peg-tMG RNA and
mAb198 showed a signi¢cantly lower loss of the AChR (ap-
proximately 17% AChR loss). On the other hand, tMG RNA
showed only partial protection from AChR loss induced by
mAb198 (39% AChR loss), compared with Peg-tMG RNA,
con¢rming the enhancement of in vivo bioavailability of the
RNA aptamer by PEG conjugation. Animals injected with
Peg-Scr. RNA and mAb198 did not show any protection
from AChR loss (49% AChR loss), compared with animals
with the antibody alone, con¢rming the speci¢c protection of
animal neuromuscles from AChR loss induced by the anti-
body with the Peg-tMG RNA aptamer. Thus, it was con-
cluded that Peg-tMG RNA could e¡ectively inhibit
mAb198-mediated passive transfer of EAMG in animals.
The pathogenic occurrence of autoimmune responses in
MG patients could be potentially modulated with small mol-
ecules that bind the combining site of autoantibodies, and
hence inhibit their interaction with the MIR of the autoanti-
gen, AChR. Thus, MIR mimotopes, such as short peptides
against autoantibody, or anti-AChR Fab fragments have been
developed as protectors of cells from the autoantibodies [5^7].
However, di⁄culties in isolating short peptide binding target
proteins with high a⁄nity [25] or possible AChR loss by the
Fab fragment in MG patients [6] might limit their clinical
applicability. As an alternative anti-MG therapeutic candi-
date, we have previously isolated a speci¢c RNA aptamer
with high avidity against anti-AChR antibody. In this study,
we observed that the RNA aptamer could e⁄ciently protect
animals from EAMG passively induced by the antibody. For
the enhancement of in vivo bioavailability of the RNA ap-
tamer, we truncated and modi¢ed the RNA with PEG. This
modi¢ed RNA aptamer retained both high binding a⁄nity to
the antibody and e¡ective bioactivity blocking AChR on hu-
man cells from the autoantibodies. Importantly, the modi¢ed
RNA aptamer alone neither induced EAMG nor showed any
loss of AChR in animals. Moreover, short oligonucleotides
such as RNA aptamers are intrinsically poor antigens, and
they are appropriate for chemical synthesis at a large-scale.
These results combined with previous observations [14^16],
therefore, strongly suggest that RNA aptamer against anti-
AChR antibody could be an attractive lead compound for
the development of speci¢c and non-toxic anti-MG drugs.
However, heterogeneous populations of anti-AChR autoanti-
bodies present in MG patient sera [26] will probably limit the
clinical utility of the RNA. Indeed, the single kind of RNA
aptamer against only mAb198 cross-reacted poorly with other
anti-MIR antibodies, inhibited bioactivity of autoantibodies
only from a limited number of patients at a certain level,
[14,15] and hardly protected EAMG actively induced by im-
munization with AChR in animals (data not shown). There-
fore, to be therapeutically valuable, it should be worthwhile to
isolate RNA aptamers against additional anti-MIR antibod-
ies, or a pool of various autoantibodies in MG patients. If a
combination of such RNAs prevents the binding of a wider
variety of the anti-AChR autoantibodies in MG patients, the
RNAs can then be applied to speci¢c agents against MG.
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